Skip to content


  • Poster presentation
  • Open Access

Timing chromosomal abnormalities using mutation data

  • Steffen Durinck1,
  • Christine Ho2,
  • Nicholas J Wang1,
  • Wilson Liao3,
  • Lakshmi R Jakkula1,
  • Eric A Collisson1,
  • Jennifer Pons3,
  • Sai-Wing Chan3,
  • Ernest T Lam3,
  • Catherine Chu3,
  • Kyunghee Park4,
  • Sung-woo Hong4,
  • Joe S Hur5,
  • Nam Huh4,
  • Isaac M Neuhaus3,
  • Siegrid S Yu3,
  • Roy C Grekin3,
  • Theodora M Mauro3,
  • James E Cleaver3,
  • Pui-Yan Kwok3,
  • Philip E LeBoit6,
  • Gad Getz7,
  • Kristian Cibulskis7,
  • Jon C Aster8,
  • Haiyan Huang2,
  • Elizabeth Purdom2,
  • Jian Li9, 10,
  • Lars Bolund9, 10,
  • Sarah T Arron3,
  • Joe W Gray1, 11,
  • Paul T Spellman1 and
  • Raymond J Cho3
Genome Biology201112(Suppl 1):P39

Published: 19 September 2011


Chromosomal AbnormalityGene TP53Driver MutationMutation DataCapture Sequencing


Tumors accumulate large numbers of mutations and other chromosomal abnormalities because of a breakdown in genomic repair mechanisms, which is a hallmark of tumors. Not all of these abnormalities are thought to be crucial for tumor growth and progression, and it is a question of great importance to try to identify critical abnormalities, particularly as possible targets for treatment. A strong indicator of the importance of an abnormality is the order in which it occurred relative to other abnormalities, with triggering events likely to have occurred earlier.


In general, we cannot directly observe the temporal progression of a tumor; however, for some types of chromosomal gains and losses, the mutations within the event can be classified as having occurred before or after the event by virtue of being homozygous or heterozygous. The simplest case is copy-neutral loss of heterozygosity (CN-LOH), in which it is reasonable to assume that homozygous mutations occurred before the LOH event and that heterozygous mutations occurred after the LOH event. Using sequencing data, we developed a probabilistic model for the observed allele frequency of a mutation, which allows us to estimate the true proportion of pre- and post-event mutations. Specifically, we modeled the number of reads with the mutation as a mixture model of binomials and estimated the mixing proportion. On the basis of this model, we can estimate this proportion for all LOH events within a sample and give a temporal ordering to the events within a sample. We applied this method to exome capture sequencing data that were obtained from eight primary cutaneous squamous cell tumors and matched normal pairs [1].


An immediate novel result of the analysis was that CN-LOH of chromosome 17p was temporally ordered as the first event (among CN-LOH events) in all four of the eight tumors that had CN-LOH of this region. The well-known tumor suppressor gene TP53 is located in the CN-LOH region and has pre-CN-LOH mutations in all of the samples, further strengthening the role of TP53 as a trigger for tumor progression.


Our method gives novel insight into the biology of tumor progression through a quantitative evaluation of temporal ordering of chromosomal abnormalities. Moreover, it yields a quantitative measure for comparing samples to highlight driver mutations and events.

Authors’ Affiliations

Life Sciences Division, Lawrence Berkeley National Laboratories, Berkeley, USA
Department of Statistics, University of California, Berkeley, USA
Department of Dermatology, University of California, San Francisco, USA
Emerging Technology Research Center, Samsung Advanced Institute of Technology, Giheung-gu, Yongin-si Gyeonggi-do, Korea
Samsung Electronics Headquarters, Seoul, Korea
San Francisco Dermatopathology Service, San Francisco, CAUSA
The Eli and Edythe L Broad Institute of Harvard and MIT, Cambridge, USA
Department of Pathology, Brigham and Women’s Hospital, Boston, USA
Beijing Genomics Institute-Shenzhen, Shenzhen, China
Institute of Human Genetics, Aarhus University, Aarhus, Denmark
Biomedical Engineering Department, Oregon Health and Science University, Portland, USA


  1. Durinck S, Ho C, Wang N, Liao W, Jakkula LR, Collisson EA, Pons J, Chan SW, Lam ET, Chu C, Park K, Hong SW, Hur JS, Huh N, Neuhaus IM, Yu SS, Grekin RC, Mauro TM, Cleaver JE, Kwok PY, LeBoit PE, Getz G, Cibulskis K, Aster JC, Huang H, Purdom E, Li J, Bolund L, Arron ST, Gray JW, et al.: Temporal dissection of tumorigenesis in primary cancers.Cancer Discov 2011, 1:OF1-OF7.View ArticleGoogle Scholar


© BioMed Central Ltd 2011